Loading clinical trials...
Loading clinical trials...
SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
The investigators will employ a double-blinded randomized placebo control trial to determine the effects of 12 weeks of sodium glucose co-transporter 2 (SGLT2) inhibition with empagliflozin (10 mg daily), or matching placebo. Empagliflozin has been shown to decrease cardiovascular events and arterial stiffness in different populations. Placebo will be included for comparison purposes as empagliflozin is not a standard therapy for aging-associated arterial stiffness.
Age
60 - 80 years
Sex
ALL
Healthy Volunteers
Yes
University of Missouri
Columbia, Missouri, United States
Start Date
August 18, 2024
Primary Completion Date
October 31, 2028
Completion Date
February 28, 2029
Last Updated
February 6, 2026
80
ESTIMATED participants
Empagliflozin 10 MG
DRUG
Placebo
DRUG
Lead Sponsor
University of Missouri-Columbia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions